Kornimate/medical-research-clean huggingface dataset:
post facilitation stretch versus active isolated stretching along with deep friction massage in wallet sciatica.

Conditions: Wallet Sciatica

Summary: to compare the effects of post facilitation stretch and active isolated stretch along with deep friction massage on pain pressure threshold of trigger points, disability, muscle length, and hip joint range of motion in wallet sciatica.

literature shows the effectiveness of both techniques post facilitation stretch and active isolated stretch but didn't report any comparison. in this study, investigator diagnosed the patients with wallet sciatica who came with the complaint of low back pain. both techniques were compared to determine the effectiveness in patients with wallet sciatica having trigger points.

Eligibility criteria:
inclusion criteria: * pain (grade greater than 3) * chronic pain (greater than 3 months) buttock pain. * patients with piriformis tightness less than 40 degrees. * patients with active trigger points of the piriformis. exclusion criteria: * patient with tumor * patients with cognitive problems. * recent or history of hip trauma or injury. * recent abdominal surgery. * any other orthopedic or neurological condition of hip and lumbar spine

Keywords: active isolated stretching deep friction massage post facilitation stretching piriformis syndrome
quantification of parkinson's disease patients as a biomarker for classification, prediction and response to treatment

Conditions: Parkinson Disease

Summary: this is a three-armed open investigational study that aims to differentiate, quantify, and categorize abnormal eye movements and upper limbs movements in patients with parkinson's disease. the study is using investigational non-invasive devices for that reason including anliva® hand movement and anliva® eye movement.

to evaluate performance of mathematical models developed to quantify and classify symptoms and disease state using sensor data from smart phone and eye tracking cameras in subjects with parkinson's disease. a clinical investigator will be capturing data from the clinical encounter completed by default the same day in addition to other clinical questionnaires subjects will be filling themselves. a percentage of subjects will be asked prior to their arrival to be part of a subset study called off/on study, where they will be asked not to take their ipd oral home medications prior to arrival. both study procedure elements will be performed at the beginning of the evaluation and 60 minutes after taking their medication. there is also a longitudinal study part, where a percentage of the subjects will be asked to visit the clinic with 6 months interval, up to 4 times, including the first visit. there will be a percentage of approached subjects that belong to the category of essential tremor (et) and healthy control (hc) used for comparison purposes. et and hc subjects will undergo the same recruitment and testing process.

Eligibility criteria:
inclusion criteria: for inclusion in the investigation, the subjects must fulfil all the below criteria prior to enrolment: 1. subjects already diagnosed with idiopathic parkinson's disease (ipd) 2. or subjects already diagnosed with essential tremor (et) 3. or subjects who are healthy controls (hc) and are not diagnosed with ipd or et 4. able to understand and sign the informed consent form. exclusion criteria: subjects that meet any of the below criteria will be excluded: 1. not able to sign the informed consent form 2. below 18 years of age 3. diagnosed with movement disorder other than ipd or et that might interfere with hand movements or eye movements (tics, myoclonus, chorea, dystonia, etc) 4. has parkinsonism not due to ipd (drug induced, functional, vascular, etc) 5. visual or physical limitations that prevent the subject from performing the baseline eye study requirements 6. being involved in the planning and conduct of the clinical investigation (applies to all sponsor management staff, investigational staff and third-party vendors as applicable)

Keywords: quantification biomarker classification
a clinical trial investigating the comparison of three different concentrations of nn9535 in healthy male subjects

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the aim of this clinical trial is to investigate whether differences exist between three different concentrations of the drug, nn9535, administered in healthy male subjects in equal doses.


Eligibility criteria:
inclusion criteria: * healthy male subjects, based on an assessment of medical history, physical examination and clinical laboratory data at screening, as determined by the investigator * body weight between 80 kg and 110 kg (both inclusive) * body mass index (bmi) between 18 and 27 kg/m2, both inclusive * fasting plasma glucose max 108 mg/dl (6.0 mmol/l) exclusion criteria: * known or suspected allergy to trial product(s) or related products * previous participation in this trial (randomisation) * the receipt of any investigational medicinal product within 3 months prior to this trial * subjects who have had a clinically relevant illness within 4 weeks of dosing * history of or presence of cancer, diabetes, or any clinically relevant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders * regular smoking as defined by smoking 1 or more cigarettes or the equivalent amount of tobacco pr day, and unable to refrain from smoking during the entire confinement period
strengthening coronavirus disease 2019 (covid-19) surveillance in africa

Conditions: COVID-19; SARS CoV 2 Infection; COVID-19 Pandemic

Summary: the aim of this observational study was to develop, with the intended users, an epidemic surveillance and response system that will be effective, sensitive, coordinated and appropriate. the streesco project aims to * implement active epidemiological surveillance of suspected cases in benin at strategic sites in accordance with the world health organization (who) protocol, in support of the national strategy for responding to the covid-19 virus. * to strengthen this national strategy by developing a clinico-epidemiological surveillance system in remote areas of benin (health centre approach) and burkina faso (population survey approach). * to gain a better understanding of the dynamics of the epidemic and its parameters in africa thanks to a modern biostatistical and geo-epidemiological analysis of the data collected as part of this project.

within the framework of the health systems set up by the benin health authorities, the project aims to develop, with the intended users, an epidemic surveillance and response system that will be effective, sensitive, coordinated and adapted to a context where resources are limited. following the start of data collection on 01 march 2021, new reforms to the response strategy against covid-19 in benin have led the investigators to opt for a new strategy in order to meet the objectives of the study. the epidemiological surveillance system will be adapted to the reforms, and data collected and processed prospectively on the dynamics of the epidemic will be collected in covid-19 screening centres and in public and private health centres. this is the scientific data needed to issue an early warning signal and enable the healthcare system to respond appropriately. the information system will be based on (i) epidemiological surveys in the field, (ii) virological, serological and antigenic tests, (iii) indicators that will enable action to be monitored, adaptation to the epidemic to be assessed and the response capacity of health structures to be controlled. analysis (biostatistics, geo-epidemiology) of the data collected will provide useful knowledge for a better understanding of the dynamics of the epidemic. finally, the project will encourage collaboration between african and european researchers and strengthen the capacity of african institutions to set up an epidemic surveillance system.

Eligibility criteria:
inclusion criteria: * all volunteering for covid-19 screening in health units dedicated to covid-19 activities. * having benefited from a covid-19 test. * give free and informed consent to participate in the study. exclusion criteria: * subjects who did not give free and informed consent to participate in the study.

Keywords: covid-19 epidemiological surveillance benin strategic sites dynamics
medtronic cardiac surgery pmcf registry

Conditions: Valve Disease, Heart

Summary: this registry is being conducted to support ongoing post-market surveillance activities.


Eligibility criteria:
inclusion criteria: 1. patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements 2. patient has or is intended to receive or be treated with an eligible product 3. patient is within enrollment window of treatment/therapy received at the time of their initial registry enrollment, or meets criteria for retrospective enrollment exclusion criteria: 1. patient who is, or is expected to be, inaccessible for follow-up 2. patient prohibited from participation by local law 3. patient is currently enrolled in or plans to enroll in any concurrent investigational drug and/or device study that may confound results
the fvc/dlco ratio is a useful predictor of pulmonary hypertension in patients with interstitial lung disease

Conditions: Interstitial Lung Disease; Pulmonary Hypertension

Summary: pulmonary hypertension (ph) is a common disorder among patients with interstitial lung disease (ild). the symptoms are usually nonspecific and overlooked. thus, a noninvasive screening modality is recommended for early detection of ph because of its potentially significant impact on treatment strategy and clinical outcomes. objectives: to evaluate the usefulness of assessing forced vital capacity (fvc%), diffusion capacity of the lung for carbon monoxide (dlco%), and fvc%/dlco% ratio to predict pulmonary hypertension among patients with ilds.


Eligibility criteria:
inclusion criteria: * this retrospective study included all patients diagnosed with interstitial lung disease (ild) who were followed up by the chest department of a tertiary hospital between september 2016 and january 2017 exclusion criteria: * patients with occupational history * collagen vascular disease predisposing them to lung disorders * patients who could not undergo pulmonary function testing
a study of tl-925 for the treatment of ac

Conditions: Allergic Conjunctivitis

Summary: in this prospective, phase 2, randomized, double-masked, vehicle controlled study, approximately 70 eligible subjects will be randomized 1:1 to receive either tl-925 or placebo as topical ophthalmic eye drops administered bilaterally. the study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate tl-925 for the treatment of allergic conjunctivitis.


Eligibility criteria:
inclusion criteria: * individuals aged 18 years or older * female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study. * documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at visit 1 or within the past 60 months. * calculated best-corrected visual activity of 0.7 logmar or better * positive bilateral cac reaction exclusion criteria: * any systemic or ocular disease currently producing ocular redness and/or ocular discomfort, or that may interfere with the conduct of the study. * any ocular surgical intervention within the last 3 months or refractive surgery within the last 6 months * any ongoing ocular infection (bacterial, viral or fungal)
pilot study of description of cicatrisation rates of digital ulcers in systemic scleroderma

Conditions: Scleroderma, Systemic

Summary: to make an updated inventory of digital ulcer care protocols in scleroderma patients and to specify the french data on monthly healing rates and local care with patients in care centers experience, and thus to know the impact of ulcers in different dimensions to evaluate the rate of healed digital ulcers at the end of the study


Eligibility criteria:
inclusion criteria: * patient with systemic scleroderma according to the acr / eular 2012 criteria * patient with one or more active digital ulcers * patient with internet access and camera or smartphone exclusion criteria: * minor patients * patient deprived of liberty or subject to a court order * patient subject to a legal protection measure * pregnant or lactating woman * patient unable to complete the questionnaires

Keywords: scleroderma - digital ulcers
integrating artificial intelligence into lung cancer screening.

Conditions: Lung Cancer

Summary: lung cancer (lc) screening using low-dose chest ct (ldct) has already proven its efficacy. the mortality reduction associated with lc screening is around 20%, much higher than the reduction in mortality associated with screening for breast, colon or prostate cancers. implementing lung cancer screening on a large scale faces two main obstacles: 1. the lack of thoracic radiologists and ldct necessary for the eligible population (between 1.6 and 2.2 million people in france); 2. the high frequency of false positive screenings: in the nlst trial, more than 20% of the subjects screened were found to have at least one nodule of an indeterminate lung nodule (iln) whereas less than 3% of ilns are actually lc. the gold standard for determining on the benign or malignant nature of a nodule is definitive histology. otherwise, the evolution of the nodule on serial thoracic imaging is a good alternative. the period of indeterminacy of a nodule can be as long as 24 months in many cases, which can be a source of prolonged and sometimes unjustified anxiety for screening candidates. the purpose of this randomized controlled study that focuses on lc screening in patients aged 50 to 80 years, who smoked more than 20 packs/ year or stopped smoking less than 15 years ago. its objective is to determine whether assisting multidisciplinary team (mdt) meetings with an ai-based analysis of screening ldct accelerates the definitive classification of nodules into malignant or benign.


Eligibility criteria:
inclusion criteria: * age between 50 and 80 years old * active smoker or ex-smoker who quit smoking less than 15 years ago * smoking history of at least 20 pack-years * signature of the informed consent * affiliation to french social security exclusion criteria: * clinical signs suggestive of cancer * recent chest scan (\<1 year) for another cause * radiological abnormality requiring follow-up or additional investigations * health problem significantly limiting life expectancy from the clinician's point of view * health problem limiting ability or willingness to undergo lung surgery * patients with active neoplasia, except basal cell carcinoma of the skin. * vulnerable people: adults under guardianship, adults under curatorship medical and/or psychiatric problems of sufficient severity to limit full adherence to the study or expose patients to excessive risk
cold stored whole blood in cardiothoracic surgery

Conditions: Bleeding

Summary: in vitro platelet function and post-transfusion platelet recovery of platelets stored in whole blood decline during storage. in this pilot randomized clinical trial we aim to investigate the impact of storage time of whole blood on the effect and safety in treatment of immediate blood loss in patients undergoing complex cardiothoracic surgery. the study is designed as an exploratory superiority study to support feasibility and provide critical guidance for future, more definitive randomized trials. in the study the test group will receive cpd whole blood leukocyte-depleted with a platelet-sparing filter and stored for 15-21 days whereas the control group patients will receive leukocyte-depleted cpd whole blood stored for less than 7 days.

a challenge for implementation of whole blood programs in civilian health services has been an uncertainty regarding the impact of storage on the clinical effect of the whole blood transfusion, especially when it comes to platelet function which is essential to hemostasis. in vitro platelet function and post-transfusion platelet recovery decline with increasing storage time of the whole blood. in this pilot randomized clinical trial we aim to investigate the impact of storage time of whole blood on the effect and safety in treatment of immediate blood loss in patients undergoing complex cardiothoracic surgery. the study is designed as an exploratory superiority study to support feasibility and provide critical guidance for future, more definitive randomized trials. in the study the test group will receive cpd whole blood leukocyte-depleted with a platelet-sparing filter and stored for 15-21 days whereas the control group patients will receive leukocyte-depleted cpd whole blood stored for less than 7 days. a control group receiving standard care (blood component-based transfusion) may be included.

Eligibility criteria:
inclusion criteria: 1. patients undergoing cardiothoracic, cardiac, or aortic surgery 2. patients with complex surgical procedures and expected cardiopulmonary bypass (cpb) time over 120 minutes 3. patients capable of providing informed consent to participate in the study exclusion criteria: 1. patients not capable of providing informed consent to participate or who will not provide informed consent 2. patients with known congenital coagulopathies or hemostatic disorders (von willebrands disease, hemophilia etc) 3. patients with known erythrocyte- or platelet/hla antibodies 4. patients with a particular increased surgical risk with expected need of ecmo 5. patients with preoperative euroscore ii ≥ 30 5. rhd negative patient
study evaluating totelle® in menopausal symptoms and sexual function

Conditions: Hot Flashes; Sleep Disorders

Summary: to evaluate the tolerability, bleeding patterns and acceptability of totelle® 1mg administered to a population of brazilian women in a continuous combined regime for hormone replacement therapy.


Eligibility criteria:
inclusion criteria: * intact uterus * generally health postmenopausal women 45 to 60 years of age, inclusive * sexually active * no hormone replacement therapy within the 90 days immediately prior to the screening evaluation. exclusion criteria: * known or suspect estrogen-dependent neoplasia * known hypersensitivity to estrogens, progestins, or other ingredients of totelle * use of any estrogen, progestin, androgen containing medications or tibolone within 12 weeks before screening.

Keywords: menopause sleep disorder hot flashes
endothelial activation hemostasis disturbances and severe bleeding events in hyperleukocytic acute myeloid leukemia

Conditions: Leukemia, Myeloid, Acute

Summary: hyper-leukocytosis \> 50.109/l is observed in 15% of acute myeloid leukemia (aml). level of hyper-leukocytosis is linearly associated with the incidence of life threatening complications that lead to the early death in 25% of these patients. the heal project is a prospective, uni-centric, observational study that plans to include a cohort of 50 patients presenting de novo aml with hyper-leukocytosis (hl) (\> 50.109/l) and 10 controls. the aim of the study is to describe the relative proportion of various hemostasis components disturbances, endothelium alterations, platelet dysfunction and to calculate cumulative incidence of hemorrhagic and thrombotic complications as well as overall survival of patients presenting with hl aml.


Eligibility criteria:
inclusion criteria: * de novo aml * gb counts \> 50 g/l * eligible for intensive chemotherapy * no previous aml treatment exclusion criteria: * secondary aml * relapse of aml * acute promyelocytic leukemia * previous antiplatelet or anticoagulant treatment

Keywords: hemostasis
sensorimotor training in low-back pain rehabilitation

Conditions: Low Back Pain

Summary: this study evaluates the effects of additional sensorimotor training (proprioceptive postural training, ppt) to conventional therapy in the treatment of chronic low-back pain. half of the participants will receive instructed treadmill training as an active comparator against ppt. all participants receive conventional physiotherapy as prescribed by their treating medical doctors. it is expected that the ppt group will improve in postural control, proprioceptive, as well as pain and function outcomes to a significantly greater extent than the active control group.


Eligibility criteria:
inclusion criteria: * patients with musculoskeletal low back pain (non-specific low back pain) * age ≥ 18 years exclusion criteria: * known or suspected neurological diseases or lesions * traumatic injury of musculoskeletal system (fractures, tumours) * spinal pathologies (e.g., tumour, infection, fracture, and inflammatory disease) * previous spinal surgery * presence of any contraindication to exercise (fracture or cardiovascular limitations)

Keywords: proprioception postural control sensorimotor training uncontrolled manifold